These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21480669)

  • 1. Atom type preferences, structural diversity, and property profiles of known drugs, leads, and nondrugs: a comparative assessment.
    Viswanadhan VN; Rajesh H; Balaji VN
    ACS Comb Sci; 2011 May; 13(3):327-36. PubMed ID: 21480669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-free drug-likeness from fragments.
    Ursu O; Oprea TI
    J Chem Inf Model; 2010 Aug; 50(8):1387-94. PubMed ID: 20726597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scoring scheme for discriminating between drugs and nondrugs.
    Sadowski J; Kubinyi H
    J Med Chem; 1998 Aug; 41(18):3325-9. PubMed ID: 9719584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Property distribution of drug-related chemical databases.
    Oprea TI
    J Comput Aided Mol Des; 2000 Mar; 14(3):251-64. PubMed ID: 10756480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separating drugs from nondrugs: a statistical approach using atom pair distributions.
    Hutter MC
    J Chem Inf Model; 2007; 47(1):186-94. PubMed ID: 17238264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases.
    Ghose AK; Viswanadhan VN; Wendoloski JJ
    J Comb Chem; 1999 Jan; 1(1):55-68. PubMed ID: 10746014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW; Murcko MA
    J Med Chem; 1996 Jul; 39(15):2887-93. PubMed ID: 8709122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space.
    Koutsoukas A; Paricharak S; Galloway WR; Spring DR; Ijzerman AP; Glen RC; Marcus D; Bender A
    J Chem Inf Model; 2014 Jan; 54(1):230-42. PubMed ID: 24289493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADME evaluation in drug discovery. 2. Prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas.
    Hou TJ; Xu XJ
    J Chem Inf Comput Sci; 2003; 43(3):1058-67. PubMed ID: 12767165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?
    Ajay A; Walters WP; Murcko MA
    J Med Chem; 1998 Aug; 41(18):3314-24. PubMed ID: 9719583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Descriptors, physical properties, and drug-likeness.
    Brüstle M; Beck B; Schindler T; King W; Mitchell T; Clark T
    J Med Chem; 2002 Aug; 45(16):3345-55. PubMed ID: 12139446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the physicochemical properties of marketed drugs: can history foretell the future?
    Faller B; Ottaviani G; Ertl P; Berellini G; Collis A
    Drug Discov Today; 2011 Nov; 16(21-22):976-84. PubMed ID: 21782967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties.
    García-Sosa AT; Oja M; Hetényi C; Maran U
    J Chem Inf Model; 2012 Aug; 52(8):2165-80. PubMed ID: 22830445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gradual in silico filtering for druglike substances.
    Schneider N; Jäckels C; Andres C; Hutter MC
    J Chem Inf Model; 2008 Mar; 48(3):613-28. PubMed ID: 18269264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOG: Fragment Optimized Growth algorithm for the de novo generation of molecules occupying druglike chemical space.
    Kutchukian PS; Lou D; Shakhnovich EI
    J Chem Inf Model; 2009 Jul; 49(7):1630-42. PubMed ID: 19527020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-related differences in the physical property profiles of oral drugs.
    Leeson PD; Davis AM
    J Med Chem; 2004 Dec; 47(25):6338-48. PubMed ID: 15566303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting oral druglikeness by iterative stochastic elimination.
    Rayan A; Marcus D; Goldblum A
    J Chem Inf Model; 2010 Mar; 50(3):437-45. PubMed ID: 20170135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are there differences between launched drugs, clinical candidates, and commercially available compounds?
    Ohno K; Nagahara Y; Tsunoyama K; Orita M
    J Chem Inf Model; 2010 May; 50(5):815-21. PubMed ID: 20394396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do metabolites differ from their parent molecules and how are they excreted?
    Kirchmair J; Howlett A; Peironcely JE; Murrell DS; Williamson MJ; Adams SE; Hankemeier T; van Buren L; Duchateau G; Klaffke W; Glen RC
    J Chem Inf Model; 2013 Feb; 53(2):354-67. PubMed ID: 23351040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.